Patient-Partnered Collaborations for Single-Cell Analysis of Rare Inflammatory Pediatric Disease
The Chan Zuckerberg Initiative invites applications from collaborative teams bringing together patient-led rare disease organizations and research teams for 4-year research projects aimed at advancing our understanding of the fundamental science of rare diseases. The Patient-Partnered Collaborations for Single-Cell Analysis of Rare Inflammatory Pediatric Disease RFA aims to support the application of single-cell biology methods to rare inflammatory pediatric diseases that will clarify cellular mechanisms of disease, understand disease heterogeneity, and improve biomarker identification or diagnostics.
Awards are $2,000,000 USD total costs for four years for each project (distributed amongst research institutions and a patient organization). The award period for each RFA is an initial two years of funding, followed by an additional two years, pending evaluation. Applicants are welcome to apply to both this opportunity and the Patient-Partnered Collaborations for Rare Neurodegenerative Disease RFA; however, the application and scope of work must be distinct.
For more information about the Patient-Partnered Collaborations RFAs, watch the informational webinar and read the FAQ.
- Learn about our grantees.